51552-16-0

Basic information

• Product Name: (Dimethylamino)acetyl chloride
• Synonyms: (Dimethylamino)acetyl chloride
• CAS NO: 51552-16-0
• Molecular Formula: C₄H₈ClNO
• Molecular Weight: 121.57
• Mol File: 51552-16-0.mol

Chemical Properties

• Melting Point: 110-113℃
• Boiling Point: 114.8 °C at 760 mmHg
• Flash Point: 23.2 °C
• Appearance: /
• Density: 1.101 g/cm³
• PKA: 6.79±0.28(Predicted)
• CAS DataBase Reference: (Dimethylamino)acetyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: (Dimethylamino)acetyl chloride(51552-16-0)
• EPA Substance Registry System: (Dimethylamino)acetyl chloride(51552-16-0)

Safety Data

• Hazardous Substances Data: 51552-16-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(Dimethylamino)acetyl chloride is used as a reagent for the synthesis of novel amino-pyrimidine inhibitors. These inhibitors play a crucial role in targeting insulin-like growth factor 1 (IGF-1) and insulin receptors kinase. The application of this compound in the pharmaceutical industry is significant due to its ability to enhance cell potency and improve hERG inhibition, which are essential factors in the development of effective drugs for various diseases.
In the field of drug discovery, (Dimethylamino)acetyl chloride is employed as a key intermediate in the synthesis of potential therapeutic agents. Its unique reactivity allows for the creation of new chemical entities with improved pharmacological properties, such as increased potency, selectivity, and reduced side effects. This makes it a valuable tool in the ongoing efforts to develop innovative treatments for a wide range of medical conditions.
Furthermore, (Dimethylamino)acetyl chloride can also be used in the development of drug delivery systems, where its reactivity can be harnessed to create novel carriers for targeted drug delivery. This application can potentially improve the bioavailability and therapeutic outcomes of various drugs, making it an important component in the advancement of pharmaceutical technology.

Upstream product

• 1118-68-9 dimethylaminoacetic acid 
• 2491-06-7 N,N-dimethylglycine hydrochoride 

Downstream Products

• 73823-86-6 N,N-diethyl-glycine 4,5-dihydro-thiazol-2-ylamide 
• 31208-89-6 Dimethylamino-thioessigsaeure- 
• 650628-76-5 N₁-[4-(hydroxymethyl)phenyl]-N₂,N₂-dimethylglycinamide 
• 108868-61-7 (3S,4S)-1-<<<(dimethylamino)methyl>carbonyl>amino>-3-hydroxy-4-<(tert-butoxycarbonyl)amino>-5-cyclohexylpentane 
• 21760-52-1 2-Dimethylamino-N-((2S,3S)-2,3-diphenyl-cyclopropylmethyl)-acetamide 
• 1188424-65-8 10-(2-(dimethylamino)acetamido)-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydro-7,10-ethanopyrimido[1,2-a]azepine-2-carboxamide 
• 1361951-26-9 2-(dimethylamino)-1-(4-(((3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)methyl)piperidin-1-yl)ethanone 

Relevant articles and documents

Testosterone 17β-N,N-dimethylglycinate hydrochloride: A prodrug with a potential for nasal delivery of testosterone

The purpose of this study was to examine the potential of the nasal route for the systemic delivery of the poorly water-soluble drug testosterone (TS) using a water-soluble prodrug, TS 17β-N,N-dimethylglycinate hydrochloride. The physicochemical properties of the prodrug, in vitro hydrolysis in human liver homogenate, and in vivo nasal and intravenous experiments were performed in rats. The aqueous solubility of the prodrug was more than 100 mg/mL, compared with 0.01 mg/mL for TS, and its log partition coefficient between 0.05 M, phosphate buffer (pH 6) and octanol was 2.4. The prodrug was found to generate TS in 33% human liver homogenate and was absorbed from the nasal cavity rapidly and quantitatively. The bioavailabilities of both the prodrug and TS after nasal administration of the prodrug were similar to that after equivalent intravenous doses. These studies in rats suggest that this water-soluble prodrug of TS may have therapeutic utility for the management of TS deficiency.

NOVEL ISOINDOLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF

Disclosed are a novel isoindoline derivative, a pharmaceutical composition and use thereof. The compound of formula I, or the pharmaceutically acceptable salt, solvate, polymorph, co-crystal, stereoisomer, isotopic compound, metabolite or prodrug thereof disclosed in the invention can regulate the generation and/or activity of PDE4 and/or TNF-α so as to effectively treat cancer and inflammatory diseases.

Simple Modular Synthetic Approaches to Asymmetric NN'N'', NN' C, or NN' P -Type Amido Pincer Ligands: Synthesis, Characterisation, and Preliminary Ligation Studies

A simple modular approach is presented which has been directed towards the synthesis of potentially monoanionic NN'N'', NN'C, and NN'P pincer-type ligands. These pincers incorporate an amide functionality derived from the skeletal structure of readily available 2-(2-aminophenyl)-4,5-dioxooxazoles. All of the pincers are synthesized in moderate yields (up to 74%) and are characterised by nuclear magnetic spectroscopy (NMR), elemental analyses, and infrared (IR) spectroscopy. X-ray crystallography is also performed on the chiral and achiral alkyl halide precursors and on an oxide derivative of a pincer with a NN'P-atom donor set. A palladium derivative of one of the NN'N''-pincers is shown to be an active catalyst for the addition of an allyl group to various benzaldehydes using n-Bu3Sn(allyl) as allyl source.

IMPROVED COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS

The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.

Synthesis of nitrogen bicyclic scaffolds: Pyrimido[1,2-a]pyrimidine-2,6- diones

The multi-step synthesis of 1,3,7-trisubstituted pyrimido[1,2-a] pyrimidinediones starting from isothiocyanates is described. These nitrogen bicycles were prepared by an iterative sequence of functionalization/ cyclocondensation reactions. [4+2] Cycloaddition reactions took place between diazadienic chains and various acyl chlorides providing sophisticated heterobicycles.

Synthesis, cleavage, and antifungal activity of a number of novel, water-soluble ester prodrugs of antifungal triazole CS-758

In this study, the synthesis and evaluation of a number of esters of CS-758 as injectable prodrugs are described. Phosphoryl ester 1a was soluble in water (>30 mg/mL) and was converted to CS-758 in human liver microsome. It was also converted to CS-758 in rats after iv administration, wherein the bioavailability of CS-758 was 53%. Compound 1a (iv) reduced the viable cell counts in kidneys in a murine systemic Candida albicans infection model, wherein the effect was comparable to or slightly superior to that of CS-758 (po). The prodrug 1a proved to be a promising injectable antifungal agent whose further evaluation is warranted.

Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-Amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b] pyrazol-3-yl)-quinolines

A novel series of 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b] pyrazol-3-yl)-quinolines was synthesized and their TβR-1 inhibitory, p38 MAPK inhibitory, and TβR-1-dependent cellular activity were evaluated. Compound 5a was found to be a highly potent in the enzyme assay and TβR-1-dependent cellular assays. In addition, dimer (4g), with a urea linker, shows a similar enzyme and cellular activity despite a bulky substitution.

ACYLATED AND NON-ACYLATED IMIDAZO[2,1-b]-1,3,4,-THIADIAZOLE-2-SULFONAMIDES, AND USES THEREOF

This invention relates to novel compounds of Formula (I): and the use of compounds of Formula (I) in the treatment of neuronal disorders of the central and peripheral nervous systems and for the treatment of proliferative diseases, such as cancer.

Antithrombotic agents

This application relates to a compound of formula (I), a pharmaceutically acceptable salt of the compound, or a prodrug thereof, as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

Synthesis and nucleic acid-binding properties of water-soluble porphyrins appending platinum(II) complexes

We synthesized two water-soluble porphyrins appending platinum(II) complexes |α,β(4a) and α,α-(4b) 5,15-bis(2-trans-[PtCl(NH3)2| N-2-aminoethylaminocarbonylphenyl) 2,3,7,8,12,13,17,18-octamethylporphyrin] and studied their reactions